Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

MLA

F. Bazan, et al. “Systemic High-Dose Intravenous Methotrexate in Patients with Central Nervous System Metastatic Breast Cancer.” BMC Cancer, vol. 19, no. 1, Nov. 2019, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s12885-019-6228-6.

APA

F. Bazan, E. Dobi, B. Royer, E. Curtit, L. Mansi, N. Menneveau, M. J. Paillard, G. Meynard, C. Villanueva, X. Pivot, & L. Chaigneau. (2019). Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer. BMC Cancer, 19(1), 1–6. https://doi.org/10.1186/s12885-019-6228-6

Chicago

F. Bazan, E. Dobi, B. Royer, E. Curtit, L. Mansi, N. Menneveau, M. J. Paillard, et al. 2019. “Systemic High-Dose Intravenous Methotrexate in Patients with Central Nervous System Metastatic Breast Cancer.” BMC Cancer 19 (1): 1–6. doi:10.1186/s12885-019-6228-6.